Business
Ensysce Biosciences Issues Annual Shareholder Letter
PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch FDA Aligned with ENSC Manufacturing Path for PF614, Enabling Commercial Scale Up MPAR® Patent Protection Extended Through 2042 Up to $20 Million in Funding Secured to ...
About this update from Ensysce Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA Aligned with ENSC Manufacturing Path for PF614, Enabling Commercial Scale Up","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"MPAR® Patent Protection Extended Through 2042","length":53,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to $20 Million in Funding Secured to Advance Late-Stage Programs","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":275,"olType":false},{"type":"text","content":"SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 5, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today issued its 2025 annual letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick.","length":404,"tagName":"p"},{"type":"text","content":"Dear Fellow Shareholders,","length":25,"tagName":"p"},{"type":"text","content":"2025 was a year of meaningful execution and strategic advancement for Ensysce. I would like to thank our shareholders for your continued support as we advance our mission to deliver safer, more responsible opioid analgesics without compromising access to effective pain relief. Over the past year, we made substantial progress across clinical development, regulatory alignment, intellectual property, and financing- strongly positioning the Company for 2026 and beyond.","length":469,"tagName":"p"},{"type":"text","content":"Our efforts in 2025 were centered on advancing our clinical programs built on Ensysce's proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technology platforms. Together, these platforms are designed to fundamentally improve the safety profile of opioid medications by addressing both abuse and overdose risk while preserving therapeutic efficacy.","length":395,"tagName":"p"},{"type":"text","content":"TAAP™ Program Update: PF614","length":27,"tagName":"p"},{"type":"text","content":"Our lead clinical candidate, PF614, is an extended-release oxycodone analgesic incorporating TAAP™ technology. PF614 potentially represents a new cl...